logo-loader
viewAlliance Pharma PLC

Alliance Pharma plc boss John Dawson discusses transformation since Sinclair acquisition

Alliance Pharma chief executive John Dawson speaks to Proactive Investors’ Stocktube about interim results, released today, which show a business transformed by a major acquisition.
“We took on a business that was the equivalent size of us, so you put the two together and you double your sales and you double your profits,” Dawson says.
“It has given us greater scale.”
Dawson added that as a larger group Alliance is taken more seriously by investors and it is a better candidate for new opportunities.
He also discusses the other highlights for the six month period, looks forward to the remaining months of 2016 and talks future acquisitions.

Quick facts: Alliance Pharma PLC

Price: 87 GBX

AIM:APH
Market: AIM
Market Cap: £4.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Alliance Pharma PLC named herein, including the promotion by the Company of Alliance Pharma PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'It's never been so busy and exciting', says Alliance Pharma PLC CEO

Alliance Pharma plc (LON:APH) said revenues had more than doubled and trading profits for the year to the end of December were in line with City forecasts as it provided investors with a progress report. The speciality pharma company said it expects sales to be £97.5mln - up from £48.3mln...

on 24/1/17

2 min read